Gil Salóm Manuel
Instituto Valenciano de Infertilidad, Valencia, España.
Arch Esp Urol. 2004 Nov;57(9):1035-46.
The introduction of intracytoplasmic spermatozoid injection (ICSI) not only has improved significantly the prospects of fertility after assisted reproduction by using spermatozoa recovered from the seminal tract, but also has allowed extension of the spectrum of recovery techniques. For obstructive azoospermia, it is currently possible to use not only spermatozoa obtained by microsurgical techniques from the epididymis (MESA), but also spermatozoa obtained from the testicle by means of testicular biopsy (TESE), or spermatozoa percutaneously aspirated from the testicle/epididymis by minimally invasive techniques (TESA, PESA). Minimal requirements in terms of spermatic quality for ICSI have also allowed to successfully criopreserve epididymal and testicular spermatozoa. ICSI results are not influenced by the origin of spermatozoa (epididymis or testicle), neither by the technique of spermatic recovery. Fresh or criopreserved spermatozoa microinjections are not different either. On the other side, 40-60% of patients with secretory azoospermia show small foci with preserved spermatogenesis in their testicles. For ICSI, these scarce spermatozoids may also be extracted from the testicle by multiple open biopsies, percutaneous aspiration, or microsurgical biopsies (micro-TESE). Nevertheless, in secretory azoospermia the yield of percutaneous techniques is lower than open or microsurgical procedures. It is also possible to criopreserve testicular spermatozoa in secretory azoospermia without the process significantly influencing ICSI results. Finally, spermatozoid testicular recovery by biopsy or percutaneous aspiration followed by ICSI has also been employed as a resource in patients with necrozoospermia and anejaculation.
胞浆内单精子注射(ICSI)的应用不仅显著改善了通过从生殖道获取精子进行辅助生殖后的生育前景,还拓宽了精子获取技术的范围。对于梗阻性无精子症,目前不仅可以使用通过显微外科技术从附睾获取的精子(MESA),还可以使用通过睾丸活检从睾丸获取的精子(TESE),或者通过微创技术经皮从睾丸/附睾抽吸的精子(TESA、PESA)。ICSI对精子质量的最低要求也使得附睾和睾丸精子能够成功冷冻保存。ICSI的结果不受精子来源(附睾或睾丸)的影响,也不受精子获取技术的影响。新鲜或冷冻保存精子的显微注射结果也没有差异。另一方面,40%-60%的分泌性无精子症患者的睾丸中存在少量生精功能保存的病灶。对于ICSI,这些稀少的精子也可以通过多次开放性活检、经皮抽吸或显微外科活检(micro-TESE)从睾丸中提取。然而,在分泌性无精子症中,经皮技术的精子获取率低于开放性或显微外科手术。在分泌性无精子症中,冷冻保存睾丸精子也不会显著影响ICSI的结果。最后,对于死精症和射精障碍患者,通过活检或经皮抽吸从睾丸获取精子后进行ICSI也已成为一种治疗手段。